ID
31013
Description
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin
Keywords
Versions (1)
- 7/10/18 7/10/18 -
Copyright Holder
see clinicaltrials.gov
Uploaded on
July 10, 2018
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755
General Medical History
- StudyEvent: ODM
Description
Demographics
Alias
- UMLS CUI-1
- C1704791
Description
Previous Diagnosis; Previous Condition
Alias
- UMLS CUI-1
- C0332132
Description
Diagnosis/Condition
Data type
text
Alias
- UMLS CUI [1,1]
- C0011900
- UMLS CUI [1,2]
- C0012634
Description
Date of Onset
Data type
date
Alias
- UMLS CUI [1]
- C0574845
Description
Disease Status
Data type
text
Alias
- UMLS CUI [1,1]
- C0012634
- UMLS CUI [1,2]
- C0449438
Similar models
General Medical History
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0012634 (UMLS CUI [1,2])
No comments